Acute lymphoblastic leukemia (ALL) treatment is evolving at a rapid pace, and many HCPs may see only a few patients with B-cell
precursor ALL per year. The goal of the CatALLyst™ initiative created by Amgen Oncology is to inform HCPs about the latest
considerations for treating ALL, starting with MRD.

Find out more about
MRD, and continue
the dialogue!

Image of leukemic cells Image of leukemic cells

Why is CR not enough?

Quantifying MRD Quantifying MRD

How is MRD quantified?

HCP Holding MRD Pathology Report HCP Holding MRD Pathology Report

Considerations for an MRD pathology report

Videos-from-your-peers Videos-from-your-peers

Videos: Hear from your peers

ALL, acute lymphoblastic leukemia; CR, complete remission; HCP, healthcare professional; MRD, measurable residual disease.

Reference: Samra B, Jabbour E, Ravandi F, et al. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
J Hematol Oncol. 2020;13:70.

Back to top